Ketamine and the potential role for rapid-acting antidepressant medications
Open accessThe DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
Ketamine appears to be the first medication to produce a rapid, although short-lasting, antidepressant response. This finding emerges from two studies: the first was a pilot study published in 2000 by a group of investigators at Yale University [1], and the second was a larger study published last year by an investigative team based at the U.S. National Institute of Mental Health Intramural Research Program [2]. Both studies make the same essential points: 1) depressed patients who had not responded to other antidepressant treatments began to show an antidepressant response within hours of ketamine administration that was significantly better than placebo, 2) for a subgroup of patients (it is difficult to estimate the true size of this group given the small sample sizes for the two studies) this response constituted a remission of their depressive symptoms, 3) that the antidepressant response to a single dose of ketamine persisted for a week or more in some patients, 4) that ketamine administration in these patients was associated with transient cognitive impairments and perceptual changes consistent with psychotigenic effects of ketamine reported in healthy individuals, and 5) overall, ketamine was safe and well-tolerated by the depressed patients studied to date. It is important to note that ketamine is not the first rapid-acting antidepressant treatment identified. That distinction probably belongs to sleep deprivation, whose transient antidepressant effects have been known for over 35 years [3], but whose underlying mechanisms still remain unclear. One can imagine many uses for a rapid-acting antidepressant medication. For example, it might be used to prevent suicide, to reduce the need for hospitalisation for psychiatric patients, to minimise depression-related disability or social disruption, and to simply reduce the distress associated with an episode of depression. However, a medication that induces a transient remission of depression is not, by itself, a treatment for depression. A critical question is whether a rapid-acting antidepressant can play a role within “real world” treatment planning. To this end, we need to know the answers to many questions including: 1) can ketamine be administered repeatedly or combined with another treatment to sustain improvement in depression; 2) does ketamine produce any adverse effects with regard to subsequent antidepressant response; 3) is there any risk of long-lasting psychoses after ketamine administration; 4) may ketamine be administered safely to bipolar depressed patients as well as unipolar depressed patients; 5) are there ways to predict who will respond favourably to ketamine?
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Glutamate and GABA systems as targets for novel antidepressant and mood-stabilizing treatments
Krystal, J. H., Sanacora, G., Blumberg, H., Anand, A., Charney, D. S., Marek, G., Epperson, C. N., Goddard, A., & Mason, G. F. (2002) · Molecular Psychiatry · doi:10.1038/sj.mp.4001021 · Cited by 553
Self-citationA Double-Blind, Placebo-Controlled Study of Memantine in the Treatment of Major Depression
Zarate, C. A., Singh, J. B., Quiroz, J. A., De Jesus, G., Denicoff, K. K., Luckenbaugh, D. A., Manji, H. K., & Charney, D. S. (2006) · American Journal of Psychiatry · doi:10.1176/appi.ajp.163.1.153 · Cited by 387
Cited by
mTOR-Dependent Synapse Formation Underlies the Rapid Antidepressant Effects of NMDA Antagonists
Li, N., Lee, B., Liu, R.-J., Banasr, M., Dwyer, J. M., Iwata, M., Li, X.-Y., Aghajanian, G., & Duman, R. S. (2010) · Science · doi:10.1126/science.1190287 · Cited by 2,881
Li, N., Liu, R.-J., Dwyer, J. M., Banasr, M., Lee, B., Son, H., Li, X.-Y., Aghajanian, G., & Duman, R. S. (2011) · Biological Psychiatry · doi:10.1016/j.biopsych.2010.12.015 · Cited by 1,082
Morgan, C. J. A., Curran, H. V., & the Independent Scientific Committee on Drugs (ISCD) (2012) · Addiction · doi:10.1111/j.1360-0443.2011.03576.x · Cited by 667
Preskorn, S. H., Baker, B., Kolluri, S., Menniti, F. S., Krams, M., & Landen, J. W. (2008) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e31818a6cea · Cited by 518
Emerging role of glutamate in the pathophysiology of major depressive disorder
Hashimoto, K. (2009) · Brain Research Reviews · doi:10.1016/j.brainresrev.2009.05.005 · Cited by 381
Metadata
- Authors
- Krystal, J.
- Venue
- Swiss Medical Weekly
- Publisher
- SMW Supporting Association
- Published
- 2007-04-21
- Volume
- 137
- Issue
- 1516
- Pages
- 215-216
- ISSN
- 0036-7672 (ISSN-L)
- 1424-3997
- OpenAlex
- W2464869946
- Cited by
- 53
- References
- 2
- FWCI
- 2.55
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Ketamine and the potential role for rapid-acting antidepressant medications. https://app.cochat.ai/papers/10.4414/smw.2007.11932
- The paper
- Krystal, J. (2007). Ketamine and the potential role for rapid-acting antidepressant medications. Swiss Medical Weekly. https://doi.org/10.4414/smw.2007.11932
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.